Drug design targeting the main protease, the Achilles' heel of coronaviruses

Current Pharmaceutical Design

Volumn 12, Issue 35, 2006, Pages 4573-4590

  Yang, Haitao ^a,b   Bartlam, Mark ^a,b   Rao, Zihe ^a,b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Coronavirus; Drug design; Main protease

Indexed keywords

ANILIDE; ANTIVIRUS AGENT; CALMIDAZOLIUM; CINANSERIN; CYSTEINE PROTEINASE; DIPEPTIDYL CARBOXYPEPTIDASE; DNA VACCINE; EPOXIDE; FL 166; HESPERETIN; HEXACHLOROPHENE; ISATIN DERIVATIVE; MAC 5776; MP 576; NUCLEOCAPSID PROTEIN; PHENYLMERCURIC NITRATE; PROTEINASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; THEAFLAVIN 3,3' DIGALLATE; VIRUS PROTEIN; VIRUS SPIKE PROTEIN;

AB INITIO CALCULATION; ANTIVIRAL ACTIVITY; CORONAVIRUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SUBSTRATE; EPIDEMIC; GENE EXPRESSION; GENUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SARS CORONAVIRUS; SEQUENCE ALIGNMENT; SEVERE ACUTE RESPIRATORY SYNDROME; SPECIES DIFFERENCE; VIRUS PNEUMONIA; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; COMPUTER-AIDED DESIGN; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDYL-DIPEPTIDASE A; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS; SUBSTRATE SPECIFICITY; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 33751551251     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206779010369     Document Type: Review

References (131)

1. Siddell SG, Ziebuhr J, Snijder EJ. Coronaviruses, toroviruses, and arteriviruses. In: Mahy BWJ, ter Meulen V, editors. Topley & Wilson's Microbiology and Microbia Infections, 10th edition. London: Hodder Arnold 2005; p. 823-56.
2. Lai MMC, Holmes KV. Coronaviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001; p. 1163-79.
3. Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 2005; 3(10): e324.
4. Spaan WJM, Cavanagh D. Coronaviridae. Virus taxonomy, VIIIth Report of the ICTV. London: Elsevier-Academic Press, 2004; p. 945-62.
5. Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi H-W, Wong BHL, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005; 102(39): 14040-5.
6. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 309: 1864.
7. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, et al. Identification of a new human coronavirus. Nat Med 2004; 10(4): 368-73.
8. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79(2): 884-95.
9. Myint SH. Human coronavirus infections. In: Siddell SG, editor. The Coronaviridae. New York: Plenum Press 1995; p. 389-401.
10. Gagneur A, Sizun J, Vallet S, Legr MC, Picard B, Talbot PJ. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J Hosp Infect 2002; 51(1): 59-64.
11. Holmes KV. Coronaviruses. In: Knipe DM, Howley PM, editors. Fields' Virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins 2001; p. 1187-203.
12. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302(5643): 276-8.
13. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1967-76.
14. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1953-66.
15. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003 J; 362(9380): 263-70.
16. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361(9366): 1319-25.
17. Pereira HG. In: Porterfield JS Ed, ANDREWES' Viruses of Vertebrates, London, Baillìre Tindall 1989; 42-57.
18. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004; 101(17): 6641-6.
19. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004; 363(9427): 2122-7.
20. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362(9399): 1895-6.
21. Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004; 78(9): 4638-45.
22. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428(6982): 561-4.
23. Zhu MS, Pan Y, Chen HQ, Shen Y, Wang XC, Sun YJ, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett 2004; 92(3): 237-43.
24. Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis 2005; 11(7): 1016-20.
25. Ziebuhr J. The coronavirus replicase. Curr Top Microbiol Immunol 2005; 287: 57-94.
26. Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 2000; 81(Pt 4): 853-79.
27. Anand K, Yang H, Bartlam M, Rao Z, Hilgenfeld R. Coronavirus main proteinase: target for antiviral drug therapy. In: Schmidt A, Wolff MH, Weber O, editors. Coronaviruses with Special Emphasis on First Insights Concerning SARS. Basel: Birkḧuser Verlag 2005; p. 173-99.
28. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300(5624): 1394-9.
29. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003; 300(5624): 1399-404.
30. Poon LL, Chu DK, Chan KH, Wong OK, Ellis TM, Leung YH, et al. Identification of a novel coronavirus in bats. J Virol 2005; 79(4): 2001-9.
31. Vijgen L, Keyaerts E, Moes E, Thoelen I, Wollants E, Lemey P, et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol 2005; 79(3): 1595-604.
32. St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ. Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J Virol 2004; 78(16): 8824-34.
33. Penzes Z, Gonzalez JM, Calvo E, Izeta A, Smerdou C, Mendez A, et al. Complete genome sequence of transmissible gastroenteritis coronavirus PUR46-MAD clone and evolution of the purdue virus cluster. Virus Genes 2001; 23(1): 105-18.
34. Kocherhans R, Bridgen A, Ackermann M, Tobler K. Completion of the porcine epidemic diarrhoea coronavirus (PEDV) genome sequence. Virus Genes 2001; 23(2): 137-44.
35. Chouljenko VN, Lin XQ, Storz J, Kousoulas KG, Gorbalenya AE. Comparison of genomic and predicted amino acid sequences of respiratory and enteric bovine coronaviruses isolated from the same animal with fatal shipping pneumonia. J Gen Virol 2001; 82(Pt 12): 2927-33.
36. Eleouet JF, Rasschaert D, Lambert P, Levy L, Vende P, Laude H. Complete sequence (20 kilobases) of the polyprotein-encoding gene 1 of transmissible gastroenteritis virus. Virology 1995; 206(2): 817-22.
37. Bonilla PJ, Gorbalenya AE, Weiss SR. Mouse hepatitis virus strain A59 RNA polymerase gene ORF 1a: heterogeneity among MHV strains. Virology 1994; 198(2): 736-40.
38. Herold J, Raabe T, Schelle-Prinz B, Siddell SG. Nucleotide sequence of the human coronavirus 229E RNA polymerase locus. Virology 1993; 195(2): 680-91.
39. Lee HJ, Shieh CK, Gorbalenya AE, Koonin EV, La Monica N, Tuler J, et al. The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase. Virology 1991; 180(2): 567-82.
40. Bredenbeek PJ, Pachuk CJ, Noten AF, Charite J, Luytjes W, Weiss SR, et al. The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHVA59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism. Nucleic Acids Res 1990; 18(7): 1825-32.
41. Thiel V, Herold J, Schelle B, Siddell SG. Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol 2001; 75(14): 6676-81.
42. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300(5626): 1763-7.
43. Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 2002; 21(13): 3213-24.
44. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL, et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003; 331(5): 991-1004.
45. Gorbalenya AE, Donchenko AP, Blinov VM, Koonin EV. Cysteine proteases of positive strand RNA viruses and chymotrypsinlike serine proteases. A distinct protein superfamily with a common structural fold. FEBS Lett 1989; 243(2): 103-14.
46. Gorbalenya AE, Koonin EV, Donchenko AP, Blinov VM. Coronavirus genome: prediction of putative functional domains in the non-structural polyprotein by comparative amino acid sequence analysis. Nucleic Acids Res 1989; 17(12): 4847-61.
47. Liu DX, Brierley I, Tibbles KW, Brown TD. A 100-kilodalton polypeptide encoded by open reading frame (ORF) 1b of the coronavirus infectious bronchitis virus is processed by ORF 1a products. J Virol 1994; 68(9): 5772-80.
48. Lu Y, Lu X, Denison MR. Identification and characterization of a serine-like proteinase of the murine coronavirus MHV-A59. J Virol 1995; 69(6): 3554-9.
49. Ziebuhr J, Herold J, Siddell SG. Characterization of a human coronavirus (strain 229E) 3C-like proteinase activity. J Virol 1995; 69(7): 4331-8.
50. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 2003; 100(23): 13190-5.
51. Hsu M-F, Kuo C-J, Chang K-T, Chang H-C, Chou C-C, Ko T-P, et al. Mechanism of the maturation process SARS-CoV 3CL protease. J Biol Chem 2005; 280: 31257-66.
52. Lee T-W, Cherney MM, Huitema C, Liu J, James KE, Powers JC, et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J Mol Biol 2005; 353(5): 1137-51.
53. Tan J, Verschueren KHG, Anand K, Shen J, Yang M, Xu Y, et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: Molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol 2005; 354(1): 25-40.
54. Gorbalenya AE, Snijder EJ, Spaan WJ. Severe acute respiratory syndrome coronavirus phylogeny: toward consensus. J Virol 2004; 78(15): 7863-6.
55. Allaire M, Chernaia MM, Malcolm BA, James MN. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 1994; 369(6475): 72-6.
56. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994; 77(5): 761-71.
57. Mosimann SC, Cherney MM, Sia S, Plotch S, James MN. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J Mol Biol 1997; 273(5): 1032-47.
58. Birtley JR, Knox SR, Jaulent AM, Brick P, Leatherbarrow RJ, Curry S. Crystal Structure of Foot-and-Mouth Disease Virus 3C Protease: New insights into catalytic mechanism and cleavage specificity. J Biol Chem 2005; 280(12): 11520-7.
59. Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J Biol Chem 2004; 279(3): 1637-42.
60. Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 2004; 43(17): 4906-12.
61. Chen S, Chen L, Tan J, Chen J, Du L, Sun T, et al. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations. J Biol Chem 2005; 280(1): 164-73.
62. Chou CY, Chang HC, Hsu WC, Lin TZ, Lin CH, Chang GG. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 2004; 43(47): 14958-70.
63. Hsu WC, Chang HC, Chou CY, Tsai PJ, Lin PI, Chang GG. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J Biol Chem 2005; 280(24): 22741-8.
64. Shi J, Wei Z, Song J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem 2004; 279(23): 24765-73.
65. Kuang WF, Chow LP, Wu MH, Hwang LH. Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays. Biochem Biophys Res Commun 2005; 331(4): 1554-9.
66. Siddell S, Sawicki D, Meyer Y, Thiel V, Sawicki S. Identification of the mutations responsible for the phenotype of three MHV RNA-negative ts mutants. Adv Exp Med Biol 2001; 494: 453-8.
67. Liu DX, Brown TD. Characterisation and mutational analysis of an ORF 1a-encoding proteinase domain responsible for proteolytic processing of the infectious bronchitis virus 1a/1b polyprotein. Virology 1995; 209(2): 420-7.
68. Ziebuhr J, Heusipp G, Siddell SG. Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase. J Virol 1997; 71(5): 3992-7.
69. Tibbles KW, Brierley I, Cavanagh D, Brown TD. Characterization in vitro of an autocatalytic processing activity associated with the predicted 3C-like proteinase domain of the coronavirus avian infectious bronchitis virus. J Virol 1996; 70(3): 1923-30.
70. Seybert A, Ziebuhr J, Siddell SG. Expression and characterization of a recombinant murine coronavirus 3C-like proteinase. J Gen Virol 1997; 78(Pt 1): 71-5.
71. Huang C, Wei P, Fan K, Liu Y, Lai L. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry 2004; 43(15): 4568-74.
72. Hegyi A, Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J Gen Virol 2002; 83(Pt 3): 595-9.
73. Chen L, Gui C, Luo X, Yang Q, Gunther S, Scandella E, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 2005; 79(11): 7095-103.
74. Hegyi A, Friebe A, Gorbalenya AE, Ziebuhr J. Mutational analysis of the active centre of coronavirus 3C-like proteases. J Gen Virol 2002; 83(Pt 3): 581-93.
75. Lu X, Lu Y, Denison MR. Intracellular and in vitro-translated 27-kDa proteins contain the 3C-like proteinase activity of the coronavirus MHV-A59. Virology 1996; 222(2): 375-82.
76. Pinon JD, Mayreddy RR, Turner JD, Khan FS, Bonilla PJ, Weiss SR. Efficient autoproteolytic processing of the MHV-A59 3C-like proteinase from the flanking hydrophobic domains requires membranes. Virology 1997; 230(2): 309-22.
77. Ziebuhr J, Siddell SG. Processing of the human coronavirus 229E replicase polyproteins by the virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to pp1a and pp1ab. J Virol 1999; 73(1): 177-85.
78. Fan K, Ma L, Han X, Liang H, Wei P, Liu Y, et al. The substrate specificity of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun 2005; 329(3): 934-40.
79. Liu Z, Huang C, Fan K, Wei P, Chen H, Liu S, et al. Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J Chem Inf Model 2005; 45(1): 10-7.
80. Jain RP, Pettersson HI, Zhang J, Aull KD, Fortin PD, Huitema C, et al. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem 2004; 47(25): 6113-6.
81. Kao RY, Tsui WH, Lee TS, Tanner JA, Watt RM, Huang JD, et al. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 2004; 11(9): 1293-9.
82. Wu C-Y, Jan J-T, Ma S-H, Kuo C-J, Juan H-F, Cheng Y-SE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA 2004; 101(27): 10012-7.
83. Blanchard JE, Elowe NH, Huitema C, Fortin PD, Cechetto JD, Eltis LD, et al. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem Biol 2004; 11(10): 1445-53.
84. Chen L-R, Wang Y-C, Lin YW, Chou S-Y, Chen S-F, Liu LT, et al. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett 2005; 15(12): 3058-62.
85. Martina E, Stiefl N, Degel B, Schulz F, Breuning A, Schiller M, et al. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor. Bioorg Med Chem Lett 2005; 15(24): 5365-9.
86. Shie J-J, Fang J-M, Kuo T-H, Kuo C-J, Liang P-H, Huang H-J, et al. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic a,β-unsaturated esters. Bioorg Med Chem 2005; 13(17): 5240-52.
87. Shie JJ, Fang JM, Kuo CJ, Kuo TH, Liang PH, Huang HJ, et al. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem 2005; 48(13): 4469-73.
88. Liu YC, Huang V, Chao TC, Hsiao CD, Lin A, Chang MF, et al. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease. Biochem Biophys Res Commun 2005; 333(1): 194-9.
89. Parera M, Clotet B, Martinez MA. Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease. J Virol 2004; 78(24): 14057-61.
90. Jenwitheesuk E, Samudrala R. Identifying inhibitors of the SARS coronavirus proteinase. Bioorg Med Chem Lett 2003; 13(22): 3989-92.
91. Toney JH, Navas-Martin S, Weiss SR, Koeller A. Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. J Med Chem 2004; 47(5): 1079-80.
92. Chou K-C, Wei D-Q, Zhong W-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 2003; 308(1): 148-51.
93. Xiong B, Gui CS, Xu XY, Luo C, Chen J, Luo HB, et al. A 3D model of SARS-CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol Sin 2003; 24(6): 497-504.
94. Hsu JT, Kuo CJ, Hsieh HP, Wang YC, Huang KK, Lin CP, et al. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett 2004; 574(1-3): 116-20.
95. Chen CN, Lin CP, Huang KK, Chen WC, Hsieh HP, Liang PH, et al. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3, 3′-digallate (TF3). Evid Based Complement Alternat Med 2005; 2(2): 209-15.
96. Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res 2005; 68(1): 36-42.
97. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999; 96(20): 11000-7.
98. Chen LR, Wang YC, Lin YW, Chou SY, Chen SF, Liu LT, et al. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett 2005; 15(12): 3058-62.
99. Supekar VM, Bruckmann C, Ingallinella P, Bianchi E, Pessi A, Carfi A. Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc Natl Acad Sci USA 2004; 101(52): 17958-63.
100. de Groot RJ, Luytjes W, Horzinek MC, van der Zeijst BA, Spaan WJ, Lenstra JA. Evidence for a coiled-coil structure in the spike proteins of coronaviruses. J Mol Biol 1987; 196(4): 963-6.
101. Xu Y, Lou Z, Liu Y, Pang H, Tien P, Gao GF, et al. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 2004; 279(47): 49414-9.
102. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777-810.
103. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-69.
104. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004; 363(9413): 938-47.
105. Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA 2004; 101(22): 8455-60.
106. Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, et al. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun 2004; 319(3): 746-52.
107. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-4.
108. Babcock GJ, Esshaki DJ, Thomas WD Jr, Ambrosino DM. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 2004; 78(9): 4552-60.
109. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004; 279(5): 3197-201.
110. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003; 312(4): 1159-64.
111. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005; 24(8): 1634-43.
112. Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA 2005; 102(7): 2430-5.
113. He Y, Lu P, Siddiqui Y, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005; 174: 4908.
114. Pang H, Liu Y, Han X, Xu Y, Jiang F, Wu D, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004; 85: 3109-13.
115. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004; 101: 2536-41.
116. van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocap-4590 sid proteins of severe acute respiratory syndrome coronavirus. J Virol 2005; 79: 1635-44.
117. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005; 309(5742): 1864-8.
118. Egloff MP, Ferron F, Campanacci V, Longhi S, Rancurel C, Dutartre H, et al. The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci USA 2004; 101(11): 3792-6.
119. Sutton G, Fry E, Carter L, Sainsbury S, Walter T, Nettleship J, et al. The nsp9 replicase protein of SARS-coronavirus, structure and functional insights. Structure (Camb) 2004; 12(2): 341-53.
120. Zhai Y, Sun F, Li X, Pang H, Xu X, Bartlam M, et al. Insights into coronavirus transcription and replication from the structure of the SARS-CoV nsp7-nsp8 hexadecamer. Nat Struct Mol Biol 2005; 12(11); 980-6.
121. Saikatendu KS, Joseph JS, Subramanian V, Clayton T, Griffith M, Moy K, et al. Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1"-phosphate dephosphorylation by a conserved domain of nsp3. Structure (Camb) 2005; 13(11): 1665-75.
122. Bergmann C, McMillan M, Stohlman S. Characterization of the Ld-restricted cytotoxic T-lymphocyte epitope in the mouse hepatitis virus nucleocapsid protein. J Virol 1993; 67(12): 7041-9.
123. Boots AM, Van Lierop MJ, Kusters JG, Van Kooten PJ, Van der Zeijst BA, Hensen EJ. MHC class II-restricted T-cell hybridomas recognizing the nucleocapsid protein of avian coronavirus IBV. Immunology 1991; 72(1): 10-4.
124. Blicher T, Kastrup JS, Buus S, Gajhede M. High-resolution structure of HLA-A*1101 in complex with SARS nucleocapsid peptide. Acta Crystallogr D Biol Crystallogr 2005; 61(Pt 8): 1031-40.
125. Robertson MP, Igel H, Baertsch R, Haussler D, Ares M Jr, Scott WG. The structure of a rigorously conserved RNA element within the SARS virus genome. PLoS Biol 2005; 3(1): e5.
126. de Haan CA, Masters PS, Shen X, Weiss S, Rottier PJ. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 2002; 296(1): 177-89.
127. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA 2005.
128. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 2004; 101(44): 15748-53.
129. Debnath AK. Application of 3D-QSAR techniques in anti-HIV-1 drug design--an overview. Curr Pharm Des 2005; 11(24): 3091-110.
130. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 2004; 10(32): 4039-53.
131. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des 2004; 10(32): 4055-64.